Sangamo BioSciences | SGMO - Sales Revenues


Sangamo BioSciences reported $356K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Cipla INR 71.19B 5.78B Jun/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Grifols EUR 2B 306.7M Mar/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Merck USD 16.6B 310M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.95B 710M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026